8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 8, 2026·SEC
Atea Pharmaceuticals, Inc.(AVIR)Earnings, Financials & Key Ratios
AVIR•NASDAQ
$4.49
Price updated Jun 27, 2026
AboutAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$180M+6.3%
- Net Income-$158M+6.0%
- EPS (Diluted)-1.94+3.0%
- ROE-44.34%-30.9%
AVIR Price & Volume
Atea Pharmaceuticals, Inc. (AVIR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-Term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
"Atea Pharmaceuticals remains a pre-commercial biotechnology entity with zero revenue recorded over the last ten quarters, necessitating a heavy reliance on its dwindling cash reserves to fund late-stage antiviral development. While the company has attempted to manage liquidity through stock-based compensation, the persistent quarterly operating losses, which reached $48.0 million in 2026Q1, underscore significant execution risks. Investors should monitor the company's ability to reach clinical milestones before the current $79.3 million cash position is exhausted, as further capital raises appear likely to cause substantial shareholder dilution."
Verdict Logic
the company's cash position has declined to $79.3 million as of 2026Q1, creating a precarious runway that may necessitate dilutive financing to sustain operations.
AVIR Growth Metrics
Atea Pharmaceuticals, Inc. (AVIR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-27.88%
Return on Capital
10 Years-25.09%
5 Years-22.55%
3 Years-38.51%
Last Year-50.14%
AVIR Recent Earnings
Atea Pharmaceuticals, Inc. (AVIR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.57+5.0%
$0.60
Rev
—
$22M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.57-16.3%
$0.49
Rev
—
$2M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.53-15.2%
$0.46
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.44+4.3%
$0.46
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.57vs $0.60+5.0% | —vs $22M |
| Q2 2026 | Mar 5, 2026 | $0.57vs $0.49-16.3% | —vs $2M |
| Q4 2025 | Nov 12, 2025 | $0.53vs $0.46-15.2% | — |
| Q3 2025 | Aug 7, 2025 | $0.44vs $0.46+4.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Atea Pharmaceuticals, Inc. (AVIR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.49 | $359.32M | -2.31 | — | — | -44.34% | — | |
| $4.25 | $1.52B | -3.90 | 60.6% | -123.9% | -50.17% | — | |
| $60.28 | $850.49M | 66.24 | 20.03% | 14.99% | 13.98% | — | |
| $18.56 | $3.51B | -11.53 | 53.44% | -2554.14% | -43.94% | — | |
| $38.10 | $6.51B | -14.94 | — | — | -83.29% | — | |
| $4.58 | $904.72M | -26.94 | 128.21% | 83.95% | 129.32% | — |
Compare AVIR vs Peers
Atea Pharmaceuticals, Inc. (AVIR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVIR SEC Filings & Documents
Atea Pharmaceuticals, Inc. (AVIR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AVIR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVIR Frequently Asked Questions
Atea Pharmaceuticals, Inc. (AVIR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AVIR profitable?
Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $169.5M for fiscal year 2025.
Dividend & Returns
What is AVIR's return on equity?
Atea Pharmaceuticals, Inc. (AVIR) has a return on equity (ROE) of -44.3%. Negative ROE indicates the company is unprofitable.
What is Atea Pharmaceuticals, Inc.'s free cash flow?
Atea Pharmaceuticals, Inc. (AVIR) had negative free cash flow of $147.9M in fiscal year 2025, likely due to heavy capital investments.